Berenberg has initiated coverage of BioNTech (BNTX) and Moderna (MRNA), citing their leadership positions in mRNA medicine.

Fintel reports that on November 18, 2024, HSBC upgraded their outlook for Moderna (NasdaqGS:MRNA) from Hold to Buy. Analyst ...

Berenberg analyst Harry Gillis initiated coverage of Moderna (MRNA) with a Hold rating and $42 price target. The firm says mRNA will ...

Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...

Turin Art week may be focused around Artissima, Italy’s oldest art fair, but there's must-see exhibitions to found across the ...

Bird flu has spread far and wide, infecting a range of species like chickens, skunks, cows, foxes and polar bears. But it's ...

This Will Not End Well” is the incredible retrospective that the Neue Nationalgalerie dedicates to one of the most important ...

The S&P 500 added 0.4% on Monday, Nov. 18, kicking off a trading week that will feature a highly anticipated earnings report ...

API technology startup Kong Inc. said today it has closed on a bumper $175 million late-stage round of funding, bringing its ...

Shares are trading lower in Europe after gaining in Asia after U.S. stocks recovered somewhat from last week's swoon. Oil ...

Investors have been bracing for some potential downsides of Trump’s reshaping of the economy. Moderna rose 7.2% on Monday but ...

Friday was a doozy for many biotech and pharmaceutical companies after news broke late Thursday that President-elect Donald Trump would nominate vaccine skeptic Robert F. Kennedy Jr. to the nation's ...